Tricyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 514/454)
-
Publication number: 20110060037Abstract: The present invention relates to the use of NPY receptor antagonists for the preparation of a medicament for achieving a reduction in and/or prevention of abuse of psycho-stimulants, opioids and related substances.Type: ApplicationFiled: March 11, 2009Publication date: March 10, 2011Inventors: David Paul Drucker Woldbye, Gunnar Sørensen
-
Patent number: 7902228Abstract: Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.Type: GrantFiled: February 4, 2008Date of Patent: March 8, 2011Assignees: University of Iowa Research Foundation, The United States of America, National Institute of HealthInventors: David F. Wiemer, Jeffrey D. Neighbors, John A. Beutler
-
Publication number: 20110053895Abstract: The invention relates to pharmacology and medicine, in particular to a class of mitochondrially-addressed compounds which can be used in the pharmaceutical compositions of medicinal agents (preparations) for preventing and treating cardiovascular diseases and diseases and pathological conditions caused by disturbed blood circulation or oxygen supply to tissues and organs.Type: ApplicationFiled: June 29, 2007Publication date: March 3, 2011Inventors: Maxim Vladimirovich Skulachev, Vladimir Petrovich Skulachev
-
Publication number: 20110046213Abstract: ?9 THC is obtained by extracting ?9 THC and ?9 THC carboxylic acid from plant material using a non-polar solvent and decarboxylating the ?9 THC acid into ?9 THC in the same solvent, without a solvent swap, in the presence of aqueous base. The ?9 THC is then washed to remove inorganic impurities, still in the same original solvent.Type: ApplicationFiled: May 1, 2009Publication date: February 24, 2011Inventors: Parveen Bhatarah, Derek McHattie, Alan Kenneth Greenwood
-
Publication number: 20110038958Abstract: The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.Type: ApplicationFiled: December 17, 2008Publication date: February 17, 2011Applicants: GW Pharma Limited, Otsuka Pharmaceutical Co., Ltd.Inventors: Tetsuro Kikuchi, Kenji Maeda, Geoffrey Guy, Philip Robson, Colin Stott
-
Publication number: 20110033376Abstract: There is described dexanabinol, or a derivative thereof, for the treatment of melanoma. There is also described a method of treating a patient suffering from melanoma.Type: ApplicationFiled: July 4, 2008Publication date: February 10, 2011Inventors: Malcolm Philip Young, Catherine Mary Thomas, Olusola Clement Idowu, Julie Anne Charlton
-
Publication number: 20110020448Abstract: Provided is a pharmaceutical composition for the treatment and prevention of glaucoma, containing (a) a therapeutically effective amount of a compound represented by Formula 1 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.Type: ApplicationFiled: December 18, 2008Publication date: January 27, 2011Applicants: MAZENCE, INC., KT & G CORPORATIONInventors: Myung-Gyu Park, Taehwan Kwak
-
Publication number: 20110021617Abstract: The invention relates to an acidic cannabinoid for medical use and to a cannabis extract comprising an acidic cannabinoid. The extract may comprise one or more compounds selected from the group consisting of cannabidiolic acid (CBD-A), cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinolic acid (CBN-A) and cannabinol. The invention further relates to a method for preparing a preparation comprising extracting an acidic cannabinoid from cannabis.Type: ApplicationFiled: August 25, 2010Publication date: January 27, 2011Applicant: Nederlandse Organisatie voor Toegepast- Natuurwetenschappelijk Onderzoek TNOInventors: Henricus Adriaan A. J. Korthout, Kitty Catharina M. Verhoeckx, Rentje Frederik Witkamp, Robert Paul Doornbos, Mei Wang
-
Publication number: 20110021616Abstract: Methods for treating a bacterial infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with bacteria. A rhodmaine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient.Type: ApplicationFiled: May 24, 2010Publication date: January 27, 2011Applicant: KIADIS PHARMA CANADA INC.Inventors: ABDELKRIM HABI, DENIS GRAVEL, LUC VILLENEUVE, HONGSHENG SU, MARC VAILLANCOURT
-
Publication number: 20110021613Abstract: Compounds obtainable from plants, e.g. of the genus Eucalyptus, or from microorganisms are shown to be useful as CNS activity modulators useful e.g. in the treatment of depression, for lifting mood and/or for increasing behavioural initiative and the like. This use and related aspects form embodiments of the invention. Also compounds as such are presented. The compounds useful are acylphloroglucine derivatives of the formula I, wherein the substituents are as defined in the description.Type: ApplicationFiled: December 11, 2007Publication date: January 27, 2011Applicant: INTERMED DISCOVERY GMBHInventors: Ernst Roemer, Torsten Grothe
-
Publication number: 20110020217Abstract: There is described a pharmaceutical composition comprising dexanabinol, or a derivative thereof, in combination with a second therapeutic agent that targets BRAF or MEK, and a pharmaceutically acceptable adjuvant, diluent or carrier. There is also described a method of treating a patient suffering from melanoma and uses related thereto.Type: ApplicationFiled: October 10, 2008Publication date: January 27, 2011Applicant: E-THERAPEUTICS PLCInventors: Malcolm Philip Young, Catherine Mary Thomas, Olusola Clement Idowu
-
Publication number: 20110021564Abstract: The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in ADHD and ADD patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in ADHD and ADD patients. The invention also includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered with one or more other active agents. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.Type: ApplicationFiled: January 24, 2008Publication date: January 27, 2011Applicant: LCS GROUP, LLCInventor: Louis Sanfilippo
-
Publication number: 20110015158Abstract: The presently disclosed subject matter is described to metalloenzyme inhibitors having metal binding moieties linked to a targeting moiety through a linking group or a direct bond, method of screening for metalloenzyme inhibitors, and methods for treating a metalloenzyme related disorder by administering a metalloenzyme inhibitor to a subject in need of treatment thereof.Type: ApplicationFiled: December 3, 2008Publication date: January 20, 2011Applicant: Viamet Pharmaceuticals, Inc.Inventors: Robert J. Schotzinger, William J. Hoekstra
-
Patent number: 7868039Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vinca alkaloids, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vincristine. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.Type: GrantFiled: July 30, 2007Date of Patent: January 11, 2011Assignee: Cancer Research Technology LimitedInventors: William R. Wilson, Bronwyn G. Siim
-
Patent number: 7868040Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and an alkylating agent, which has anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and cyclophosphamide. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.Type: GrantFiled: July 30, 2007Date of Patent: January 11, 2011Assignee: Cancer Research Technology LimitedInventors: William R. Wilson, Bronwyn G. Siim
-
Publication number: 20110002995Abstract: Provided is a pharmaceutical composition for the treatment and prevention of cardiac diseases, containing (a) a therapeutically effective amount of a compound represented by Formula 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.Type: ApplicationFiled: December 18, 2008Publication date: January 6, 2011Applicants: MAZENCE INC., KT & G CORPORATIONInventors: Taehwan Kwak, Myung-Gyu Park
-
Patent number: 7863321Abstract: The present invention relates to synergistic combinations of the compound 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from anthracyclines and topisomerase II inhibitors, which have anti-tumor activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from etoposide, and doxorubicin. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.Type: GrantFiled: July 30, 2007Date of Patent: January 4, 2011Assignee: Cancer Research Technology LimitedInventors: William R. Wilson, Bronwyn G. Siim
-
Patent number: 7863320Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a platinum compound which has anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and carboplatin. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.Type: GrantFiled: July 30, 2007Date of Patent: January 4, 2011Assignee: Cancer Research Technology LimitedInventors: William R. Wilson, Bronwyn G. Siim
-
Publication number: 20100330157Abstract: The disclosure relates to a biomaterial that comprises an aqueous phase, polymer network, a second polymer included in said disclosure invention more particularly relates to a biomaterial including an aqueous phase and a first polymer network made of a first proteic or saccharidic polymer or a mixture of first proteic and saccharidic polymers, wherein the first polymer network and the aqueous phase define a first gel (A), the biomaterial including: a second proteic or saccharidic polymer or a mixture of the second proteic and saccharidic polymers, either in solution in the aqueous phase of the gel (A) or in the form of a gel (B), and a first enzyme for degrading said second polymer or second polymer network. The disclosure also relates to a method for making biomaterials, and to the uses of the biomaterial particularly for releasing active substances, and to a device for the controlled release of active substances that include the biomaterial.Type: ApplicationFiled: November 13, 2008Publication date: December 30, 2010Applicant: MA.I.A WoundcareInventors: Véronique Laretta-Garde, Julien Picard, Marie Cécile Klak, Sébastien Perrin, Sébastien Giraudier
-
Publication number: 20100317731Abstract: Disclosed is a medicinal composition and method of use conspiring topiramate for treating drug-induced excessive sweating (hyperhidrosis). As a further embodiment of this invention, topiramate may be administered along with another medicament that causes excessive sweating to prevent such excessive sweating. As still a further embodiment of this invention, topiramate may be administered along with another medicament that treats excessive sweating, such that the synergy of the drugs effectively treats the sweating.Type: ApplicationFiled: June 11, 2010Publication date: December 16, 2010Inventor: Elias K. Shaya
-
Publication number: 20100317729Abstract: The present invention relates to a novel pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CB1 and/or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CB1 and/or CB2 receptor. Preferably both the inverse agonist of the CB1 and/or CB2 receptor and the neutral antagonist of the CB1 and/or CB2 receptor are cannabinoids. Preferably the cannabinoids are tetrahydrocannabidivarin (THCV) and cannabidiol (CBD).Type: ApplicationFiled: July 4, 2008Publication date: December 16, 2010Applicant: GW Pharma LimitedInventors: Geoffrey Guy, Brian Anthony Whittle, Roger Pertwee
-
Publication number: 20100317730Abstract: Disclosed is a medicinal composition and method of use comprising topiramate for treating hot flashes and excessive sweating known as vasomotor symptoms related to perimenopausal or menopausal symptoms and in a still further embodiment of the invention topiramate and the medicine for treating menopause and perimenopause are provided in a kit or in unit dosage form, e.g., tablet or capsule. As a further embodiment of this invention, topiramate may be administered along with a medicament use to treat hot flashes and excessive sweating related to perimenopausal or menopausal symptoms.Type: ApplicationFiled: June 11, 2010Publication date: December 16, 2010Inventor: Elias K. Shaya
-
Publication number: 20100317732Abstract: Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): Formula (I), wherein R1, R2, R3, X1, X2, X3, a, and b are as described herein. Uses of these compounds in the preparation of a medicament are also disclosed. Also disclosed are compounds of formula (II), pharmaceutical compositions comprising such compounds and uses thereof.Type: ApplicationFiled: December 29, 2008Publication date: December 16, 2010Applicant: THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICEInventors: Curtis J. Henrich, Heidi R. Bokesch, Laura K. Cartner, Richard W. Fuller, Kirk R. Gustafson, Kentaro Takada, James B. McMahon, Susan E. Bates, Robert W. Robey, Suneet Shukla, Suresh V. Ambudkar, Michael C. Dean
-
Publication number: 20100310465Abstract: A nanodevice has a containment vessel defining a storage chamber therein and defining at least one port to provide access to and from said storage chamber, and a stopper assembly attached to the containment vessel. The stopper assembly has a blocking unit arranged proximate the at least one port and has a structure suitable to substantially prevent material after being loaded into the storage chamber from being released while the blocking unit is arranged in a blocking configuration. The stopper assembly is responsive to the presence of a predetermined stimulus such that the blocking unit is released in the presence of the predetermined stimulus to allow the material to be released from the storage chamber. The predetermined stimulus is a predetermined catalytic activity that is suitable to at least one of cleave, hydrolyze, oxidize, or reduce a portion of the stopper assembly, and the nanodevice has a maximum dimension of about 1 ?m.Type: ApplicationFiled: July 22, 2010Publication date: December 9, 2010Applicant: The Regents of the University of CaliforniaInventors: Jeffrey I. Zink, Jie Lu, Fuyuhiko Tamanoi, Andre Nel, Sarah Angelos, Fraser Stoddart, Qiaolin Chen, Tian Xia, Kaushik Patel, William Dichtel
-
Publication number: 20100310599Abstract: The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.Type: ApplicationFiled: June 15, 2010Publication date: December 9, 2010Inventors: W. Blair GEHO, John R. LAU
-
Publication number: 20100310657Abstract: Provided is a pharmaceutical composition for the treatment and prevention of kidney diseases, containing (a) a therapeutically effective amount of a compound represented by Formulae 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.Type: ApplicationFiled: December 18, 2008Publication date: December 9, 2010Applicants: MAZENCE INC., KT & G CORPORATIONInventors: Taehwan Kwak, Myung-Gyu Park, Kyoung Hoon Jung
-
Publication number: 20100311701Abstract: A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.Type: ApplicationFiled: June 2, 2010Publication date: December 9, 2010Applicants: Transform Pharmaceuticals, Inc, University Of South Florida, The Regents of the University Of MichiganInventors: Orn Almarsson, Magali Bourghol Hickey, Matthew Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
-
Publication number: 20100305152Abstract: The shikimate pathway links metabolism of carbohydrates to biosynthesis of aromatic compounds, which is an attractive target for the rational drug and herbicide design because it is essential in algae, higher plants, bacteria, and fungi, but absent from mammals. Thus, the present invention provides a method of inhibiting the growth of bacteria or fungi, especially Helicobacter pylori, through inhibiting enzymes in the shikimate pathway.Type: ApplicationFiled: May 27, 2009Publication date: December 2, 2010Applicant: NATIONAL TSING HUA UNIVERSITYInventors: WEN-CHING WANG, WEN-CHI CHENG, JINN-MOON YANG
-
Patent number: 7842822Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor beta agonists for treating Estrogen Receptor beta mediated diseases such as benign prostatic hyperplasia.Type: GrantFiled: July 31, 2009Date of Patent: November 30, 2010Assignee: Eli Lilly and CompanyInventors: Gregory Lee Durst, Bryan Hurst Norman, Timothy Ivo Richardson
-
Publication number: 20100297262Abstract: Described herein are pharmaceutical compositions and medicaments, and methods of using such pharmaceutical compositions and medicaments in the treatment of inflammation and cancer.Type: ApplicationFiled: April 16, 2010Publication date: November 25, 2010Applicant: COLBY PHARMACEUTICAL COMPANYInventors: Hirak S. Basu, David A. Zarling
-
Publication number: 20100286098Abstract: The present invention relates to the use of a substantially pure tetrahydrocannabinol (THC) or a THC containing extract in which THC is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. A further embodiment of the invention relates to the use of a substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. Additionally the substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid are used in the manufacture of a medicament for use as an adjunct therapy in the treatment of an inflammatory bowel disease.Type: ApplicationFiled: June 25, 2008Publication date: November 11, 2010Applicant: GW Pharma LimitedInventors: Philip Robson, Geoffrey Guy, Roger Pertwee, Joanna Jamontt
-
Patent number: 7824745Abstract: The present invention relates to benzochromene derivatives of the formula I where the various parameters have the meaning indicated in the text, and to liquid-crystal media which comprise these compounds, and to the use of the media in electro-optical displays, in particular in VAN-LCDs, and to the use of the compounds and physiologically acceptable derivatives thereof as therapeutic active ingredients.Type: GrantFiled: December 5, 2006Date of Patent: November 2, 2010Assignee: Merck Patent GmbHInventors: Andreas Taugerbeck, Melanie Klasen-Memmer
-
Publication number: 20100267733Abstract: Treatment of microglial cells with nicotine and THC synergistically attenuate the microglial activation. Using microglial activation, the combination of THC and nicotine interact synergistically reduced LPS induced TNF-? release, showing that the combination of THC and nicotine clinically have greater efficacy in reducing neuroinflammation with less side effects than either drug given alone. CD40 signaling was found critically involved in pathological activation of microglial cells. This invention is also relevant to peripheral inflammation as well thru macrophages. In addition, other cannabinoids and other nicotinic-like medications currently in development are also covered under this discovery.Type: ApplicationFiled: May 3, 2010Publication date: October 21, 2010Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: Roland D. Shytle, Jun Tan, Jared Ehrhart
-
Publication number: 20100261713Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.Type: ApplicationFiled: April 20, 2010Publication date: October 14, 2010Applicant: Purdue Pharma L.P.Inventor: Richard SACKLER
-
Patent number: 7812051Abstract: The present invention relates to polymer-modified quinone-containing and carbonyl-containing therapeutic agents, including polymer-modified ?-lapachone compounds, and methods of treating cancer by administering the polymer-modified therapeutic agents to a subject. Polymer-modification of therapeutic agents, such as ?-lapachone compounds, provides effective transport of polymer-modified therapeutic agents to tumor cells or tumor tissues by exploiting the EPR effect in tumor tissues.Type: GrantFiled: August 11, 2005Date of Patent: October 12, 2010Assignee: ArQule, Inc.Inventors: Mark A. Ashwell, Chiang J. Li, Manish Tandon, Yanbin Liu, Jean-Marc LaPierre, Zhiwei Jiang
-
Publication number: 20100255054Abstract: Provided is a pharmaceutical composition for the treatment and/or prevention of restenosis including (a) a therapeutically effective amount of a particular compound represented by Formula 1 and 2, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.Type: ApplicationFiled: November 26, 2007Publication date: October 7, 2010Inventors: Taehwan Kwak, Sang-ku Yoo, Myung-gyu Park
-
Patent number: 7807711Abstract: The invention relates to an acidic cannabinoid for medical use and to a cannabis extract comprising an acidic cannabinoid. The extract may comprise one or more compounds selected from the group consisting of cannabidiolic acid (CBD-A), cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinolic acid (CBN-A) and cannabinol. The invention further relates to a method for preparing a preparation comprising extracting an acidic cannabinoid from cannabis.Type: GrantFiled: August 2, 2006Date of Patent: October 5, 2010Assignee: Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk Onderzoek TNOInventors: Henricus Adriaan A. J. Korthout, Kitty Catharina M. Verhoeckx, Rentje Frederik Witkamp, Robert Paul Doornbos, Mei Wang
-
Publication number: 20100249223Abstract: The present invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of diseases or conditions that are alleviated by blockade of one or more types of TRP channel. Preferably the subset of TRP channel that is blockaded is the TRPA channel. More preferably the TRPA channel is the TRPA1 channel. Preferably the diseases or conditions to be prevented or treated include: neuropathic pain, inflammation or vasoconstriction. Alternatively the TRP channel that is blockaded is the TRPM channel. More preferably the TRPM channel is the TRPM8 channel. Preferably the diseases or conditions to be prevented or treated are cancer. More preferably the cancers to be treated include: cancer of the prostate, cancer of the breast, cancer of the colon, cancer of the lung or cancer of the skin. Alternatively the TRP channel that is blockaded is the TRPV channel. More preferably the TRPV channel is the TRPV1 channel.Type: ApplicationFiled: April 17, 2008Publication date: September 30, 2010Applicant: GW Pharma LimitedInventors: Vincenzo Di Marzo, Luciano De Petrocellis, Aniello Schiano Moriello
-
Publication number: 20100239674Abstract: Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.Type: ApplicationFiled: November 26, 2007Publication date: September 23, 2010Inventors: Taehwan Kwak, Myung-gyu Park, Sang-Ku You
-
Publication number: 20100239685Abstract: Provided is a naphthoquinone-based compound represented by Formula 1 or 2 having therapeutic effect on the treatment and/or prevention of prostate and/or testicle (seminal glands)-related diseases, and to a pharmaceutical composition of intestinal delivery system containing the same.Type: ApplicationFiled: November 26, 2007Publication date: September 23, 2010Inventors: Taehwan Kwak, Sang-Ku Yoo, Myung-gyu Park
-
Patent number: 7790765Abstract: The present invention provides sodium 6-hydroxy-2,2-dimethyl-5-oxo-3,4,5,6-tetrahydro-2H-benzo(h)chromene-6-sulfonate, and its synthesis and uses in the treatment of cancer.Type: GrantFiled: April 30, 2008Date of Patent: September 7, 2010Assignee: ArQule, Inc.Inventors: Judit Bartis, Erika Volckova, Manish Tandon, Deirdre Lowe, Martin P. Redmon
-
Patent number: 7786166Abstract: Methods and compositions for protecting muscarinic receptor(s) in a subject by administering at least one protective agent alone, in combination with other protective agents, or in combination with at least one neurologic agent.Type: GrantFiled: September 6, 2005Date of Patent: August 31, 2010Assignee: Healthpartners Research FoundationInventors: William H. Frey, II, John Randall Fawcett
-
Publication number: 20100216872Abstract: The present invention relates to a plant extract from a low-tetrahydrocannabinol (THC) variety of Cannabis sativa subsp. sativa for the treatment of disease. The invention further relates to the production of the extract and pharmaceutical compositions comprising said extract and the uses thereof.Type: ApplicationFiled: September 26, 2008Publication date: August 26, 2010Inventors: Heinz Letzel, Regina Klaeger, Rudolph Klaeger
-
Publication number: 20100215774Abstract: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin and/or other active drugs through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed.Type: ApplicationFiled: February 8, 2008Publication date: August 26, 2010Inventor: Todd Maibach
-
Publication number: 20100215739Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.Type: ApplicationFiled: June 9, 2009Publication date: August 26, 2010Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Publication number: 20100204312Abstract: This disclosure provides compositions and method useful for treating cell proliferative disorders including cancer. The disclosure provides cannabidiol derivatives and compositions thereof either alone or in combination with THC or a derivative thereof.Type: ApplicationFiled: May 16, 2008Publication date: August 12, 2010Applicant: CALIFORNIA PACIFIC MEDICAL CENTERInventors: Sean D. McAllister, Pierre-Yves Desprez
-
Publication number: 20100196488Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.Type: ApplicationFiled: February 12, 2010Publication date: August 5, 2010Applicant: GW Pharma LimitedInventor: Brian Whittle
-
Publication number: 20100189818Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.Type: ApplicationFiled: January 19, 2010Publication date: July 29, 2010Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventor: GUOCHUAN EMIL TSAI
-
Publication number: 20100184848Abstract: The present invention relates to pharmaceutical compositions comprising cannabinoids or mimics thereof. In one aspect, the invention provides transdermal formulations comprising cannabinoids or mimics thereof. In another aspect, the invention provides topical formulations comprising cannabinoids or mimics thereof. In one embodiment the formulations and compositions of the invention comprise nano colloidal silica. The formulations of the invention can be used in the therapeutic treatment of many conditions, including wherein the cannabinoids or mimics thereof are known to reduce the excessive neuronal firing characteristic of neuropathic pain. Muscle spasticity is also benefited by these formulations.Type: ApplicationFiled: July 13, 2007Publication date: July 22, 2010Inventors: William Abraham Wine, Harvey Wine
-
Publication number: 20100184849Abstract: A method for treating a cytotoxic disease by administrating compounds having a general formula X-(A)n-Y, wherein: n varies between 6 and 20; X denotes a hydrogen atom, an RaCO, RaOCO, RaNHCO or RaSO2 group, Ra being an alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl group, the groups being substituted or not, on condition that X is different from H when n is equal to 6; A denotes either a group having formula (I) or (II), wherein Ri is a hydrogen atom, an amino acid side chain, an alkyl, alkenyl, alkynyl, aryl, aralkyl or heteroaryl group, said groups being substituted or not, i being an integer of between 1 and n; Y is an NRbRc, Rb and Rc group having the same meaning as given earlier for Ra.Type: ApplicationFiled: March 3, 2010Publication date: July 22, 2010Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUInventors: Gilles Francois Roger Guichard, Jean-Paul Briand, Vincent Semetey, Patrick Neuberg